Blood Research

Cited by CrossRef (11)

  1. Evelin Kovacs-Sipos, David Holzmann, Thomas Scherer, Michael B Soyka. Nintedanib as a novel treatment option in hereditary haemorrhagic telangiectasia. BMJ Case Reports 2017:bcr-2017-219393
    https://doi.org/10.1136/bcr-2017-219393
  2. Natalia P. Arizmendez, Luke Rudmik, David M. Poetker. Intravenous bevacizumab for complications of hereditary hemorrhagic telangiectasia: a review of the literature. Int Forum Allergy Rhinol 2015;5:1042
    https://doi.org/10.1002/alr.21587
  3. Florian Huemer, Martin Dejaco, Christoph Grabmer, Thomas Melchardt, Daniel Neureiter, Georg Mayer, Alexander Egle, Richard Greil, Lukas Weiss. Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia. Wien Klin Wochenschr 2017;129:141
    https://doi.org/10.1007/s00508-016-1124-4
  4. George Ou, Cherry Galorport, Robert Enns. Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia. WJGS 2016;8:792
    https://doi.org/10.4240/wjgs.v8.i12.792
  5. Sophie Dupuis-Girod, Claire L. Shovlin, Anette D. Kjeldsen, Hans-Jurgen Mager, Carlo Sabba, Freya Droege, Anne-Emmanuelle Fargeton, Annette D. Fialla, Silvia Gandolfi, Ruben Hermann, Gennaro M. Lenato, Guido Manfredi, Marco C. Post, Catherine Rennie, Patrizia Suppressa, Ulrich Sure, Elisabetta Buscarini, Claudia Crocione, Ria Blom, Luisa Maria Botella, Fernando Brocca, Caroline Coxall, Karen T. Druckman, Didier Erasme, Paolo Federici, Christina Grabowski, Mildred Lundgren, Tone Søderman, Dara Woods. European Reference Network for Rare Vascular Diseases (VASCERN): When and how to use intravenous bevacizumab in Hereditary Haemorrhagic Telangiectasia (HHT)?. European Journal of Medical Genetics 2022;65:104575
    https://doi.org/10.1016/j.ejmg.2022.104575
  6. Quentin Maestraggi, Mohamed Bouattour, Ségolène Toquet, Roland Jaussaud, Reza Kianmanesh, François Durand, Amélie Servettaz. Bevacizumab to Treat Cholangiopathy in Hereditary Hemorrhagic Telangiectasia. 2015;94:e1966
    https://doi.org/10.1097/MD.0000000000001966
  7. Luigi F. Bertoli, Pauline L. Lee, Lauren Lallone, James C. Barton. Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia, ENG E137K, Alcoholic Cirrhosis, and Portal Hypertension. Case Rep Gastroenterol 2017;11:293
    https://doi.org/10.1159/000475748
  8. Erwing Castillo, Jeanette Prada-Arismendy. Bevacizumab as a treatment option in gastrointestinal bleeding associated to hereditary hemorrhagic telangiectasia. Case Report. Rev. Fac. Med. 2019;67:343
    https://doi.org/10.15446/revfacmed.v67n3.68417
  9. Alexandre Guilhem, Anne-Emmanuelle Fargeton, Anne-Claire Simon, Pierre Duffau, Jean-Robert Harle, Christian Lavigne, Marie-France Carette, Olivier Bletry, Pierre Kaminsky, Vanessa Leguy, Nathalie Lerolle, Dominique Roux, Marc Lambert, Thierry Chinet, Delphine Bonnet, Sophie Dupuis-Girod, Sophie Rivière, Vinicio A. de Jesus Perez. Intra-venous bevacizumab in hereditary hemorrhagic telangiectasia (HHT): A retrospective study of 46 patients. PLoS ONE 2017;12:e0188943
    https://doi.org/10.1371/journal.pone.0188943
  10. Thomas Kühnel, Kornelia Wirsching, Walter Wohlgemuth, Ajay Chavan, Katja Evert, Veronika Vielsmeier. Hereditary Hemorrhagic Telangiectasia. Otolaryngologic Clinics of North America 2018;51:237
    https://doi.org/10.1016/j.otc.2017.09.017
  11. Xiangying Meng, Rugang Zhao, Ge Shen, Dapeng Dong, Lijuan Ding, Shikai Wu. Efficacy and safety of bevacizumab treatment for refractory brain edema. 2017;96:e8280
    https://doi.org/10.1097/MD.0000000000008280
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd